Metformin-Induced ROS Upregulation as Amplified by Apigenin Causes Profound Anticancer Activity While Sparing Normal Cells

Metformin combined with apigenin increased ROS levels dramatically and decreased cell viability in various cancer cells including AsPC-1 cells, with each drug used singly having a minimal effect.